Summary

Eligibility
for people ages 65 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around
Principal Investigator
by Scott Mackin, Ph.D.Duygu Tosun, Ph.D.
Headshot of Duygu Tosun
Duygu Tosun

Description

Summary

The purpose of this research study is to characterize the mechanisms contributing to cognitive impairment and accelerated cognitive decline in Late Life Depression (LLD).

This is a non-randomized, observational, non-treatment study that originally launched in 2015, enrolling 133 participants. From the originally enrolled participants, the continuation of the ADNI-D study will enroll 120 participants which will include following participants from the original (parent) protocol and enrollment of new participants for a period of 30 months. Data from an additional 300 non-depressed subjects will be used from ADNI studies for comparison.

Depression history, symptom severity and health information will be collected at the initial visit to determine eligibility. An magnetic resonance imaging (MRI) scan, as well as amyloid (florbetapir) and tau (flortaucipr) positron emission tomography (PET) imaging will be conducted at San Francisco VA. Collection of plasma and serum for biomarkers, clinical assessments and cognitive assessments will be conducted at two time points. Blood samples will also be collected for genetic analysis.

Official Title

Characterizing Cognitive Decline in Late Life Depression: The Alzheimer's Disease Neuroimaging Initiative - Depression Project

Keywords

Major Depression, Late Life Depression (LLD), Depression, Late Life Depression, LLD, amyloid imaging, biomarkers, Depressive Disorder, Cognitive Dysfunction

Eligibility

For people ages 65 years and up

Inclusion Criteria:

  1. Individual participated in original Characterizing Cognitive Decline in Late Life Depression study or Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression Study.

Exclusion Exceptions:

  1. Antidepressant medication treatment is allowed only if the medication dose is stable for 4 weeks prior to the MRI scan.
  2. Psychotherapy interventions is allowed only if they have completed at least 4 weeks of individual or group psychotherapy intervention prior to the MRI scan.
  3. Participants taking cognitive enhancing medications will be able to enter the study.

Locations

  • UCSF accepting new patients
    San Francisco California 94143 United States
  • University of Pittsburgh completed
    Pittsburgh Pennsylvania 15213 United States

Lead Scientists at UCSF

  • Scott Mackin, Ph.D.
    Professor, Psychiatry, School of Medicine. Authored (or co-authored) 100 research publications
  • Duygu Tosun, Ph.D.
    Duygu Tosun-Turgut, PhD, is a Professor of Radiology and Biomedical Imaging at UCSF and the Founding Director of Medical Imaging Informatics and Artificial Intelligence at the San Francisco Veterans Affairs Medical Center.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of Southern California
Links
National Institute of Mental Health Laboratory of Neuro Imaging Alzheimer's Therapeutic Research Institute Related Info
ID
NCT02434393
Study Type
Observational
Participants
Expecting 120 study participants
Last Updated